Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on February 22, 2021, covering events occurring on February 18 and February 19, 2021. The filing addresses the early tender results and pricing terms of cash tender offers to purchase specific debt notes issued by the company and its wholly owned subsidiary, Celgene Corporation.
Key Financial Metrics
The filing does not provide standard operating financial metrics such as revenue, profit, cash flow, or margins. The primary financial data point disclosed is the aggregate purchase price for the tender offers, which is up to $4.0 billion.
Material Changes
The material event reported is the announcement of early tender results for the cash tender offers initiated on February 4, 2021. Additionally, the pricing terms for these offers were announced on February 19, 2021. No comparative period data is provided in this specific filing.
Guidance, Outlook, and Risks
Management commentary is limited to the execution of the tender offers. The offers are subject to the terms and conditions detailed in the Offer to Purchase dated February 4, 2021. The filing incorporates press releases (Exhibits 99.1 and 99.2) by reference for further details but does not contain explicit forward-looking guidance, risk factors, or contingency discussions within the body of this report.
Investor Verification Checklist
- Verify the specific pricing terms announced on February 19, 2021, by reviewing Exhibit 99.2.
- Confirm the final acceptance rates and total volume of notes tendered in the early results via Exhibit 99.1.
- Review the full Offer to Purchase dated February 4, 2021, to understand the conditions precedent for the $4.0 billion transaction.
- Check the status of the specific securities involved: 1.000% Notes due 2025 (BMY25), 1.750% Notes due 2035 (BMY35), and Celgene Contingent Value Rights (CELG RT).